Genomic profiling from initial assessment to detection of measurable residual disease (MRD): how NGS can rapidly deliver key insights for myeloid neoplasms

Register for this webinar and hear Craig Johnson of Automata discuss how insights from new pathology testing techniques are helping the field to bring more clarity about disease and treatments to patients across the world.